Skip to content
Screener

Travere Therapeutics, Inc. TVTX FILSPARI — Total Revenue

Other product segments

License and collaboration revenue
$2.71M-54.1%

Similar metrics at other companies

ImmunityBio, Inc. logo
IBRXOther revenues — Total Revenue
$39K+388%
PTH
PTHSNet product revenues — Total Revenue
$10.67M—
Life Time Group Holdings logo
LTHTotal center revenue — Total Revenue
$837.4M+13.8%
iRadimed logo
IRMDTotal devices revenue — Total Revenue
$15.39M+18.7%
Illumina logo
ILMNTotal product revenue — Total Revenue
$982M+7.7%
Globalstar logo
GSATTotal service revenue — Total Revenue
$60M-5.1%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K—
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
FILSPARI$105,152$55,881
Tiopronin products19,34019,980
Total net product sales$124,492$75,861

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s FILSPARI — total revenue?
Travere Therapeutics, Inc. (TVTX) reported FILSPARI — total revenue of $105.15M in Q1 2026.
How has Travere Therapeutics, Inc.'s FILSPARI — total revenue changed year-over-year?
Travere Therapeutics, Inc.'s FILSPARI — total revenue increased by 88.2% year-over-year, from $55.88M to $105.15M.
What does FILSPARI — total revenue mean?
Represents the total gross revenue generated from the sale of the specific pharmaceutical product or therapeutic asset. This metric reflects the market adoption and commercial performance of the therapy within its target patient population. It is a primary indicator of the product's growth trajectory and its contribution to the company's overall top-line performance.

Ask your AI about Travere Therapeutics, Inc.'s filspari — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude